Allon Begins Enrolment for AL-208 Phase II Clinical Trial

Allon Begins Enrolment for AL-208 Phase II Clinical Trial: "Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, today announced that patient enrolment has begun for a Phase II human clinical trial evaluating the Company's product AL-208 as a treatment for the mild cognitive impairment (MCI) that commonly occurs following coronary artery bypass graft (CABG) surgery."